Septerna Inc. SEPN and Novo Nordisk A ... The pact covers discovering, developing, and commercializing oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.

COPENHAGEN (Reuters) -Novo Nordisk (NVO) has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Novo Nordisk A/S is partnering with U.S. biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will start with four ...

executive vice president and head of Development at Novo Nordisk. “Approximately one in three adults with type 2 diabetes also have cardiovascular disease; therefore, it is crucial to have ...